LAS VEGAS, February 15, 2018 /PRNewswire/ --
FN Media Group Presents Microcapspeculators.com News Commentary
Advancements in technology are happening rapidly, continuously changing industries across the medical world. Technological inventions are especially fueling innovation in the biotechnology sector. Biotech companies are gaining new knowledge in technology and implementing this knowledge in order to push new drugs and therapies to the market. Included in today's commentary:Endonovo Therapeutics, Inc. (OTC: ENDV), Neurometrix, Inc. (NASDAQ: NURO), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Bitcoin Investment Trust. (OTC: GBTC), and Helios and Matheson Analytics Inc. (NASDAQ: HMNY).
The drug market is facing a huge battle against opioids and biotechnology companies are leaning more toward the use of technology in treating pain. The opioid epidemic has created a dire need for non-pharmacological alternatives for pain relief and many companies are working hard to make this a reality. Drug overdose deaths exceeded 59,000 in 2017, according to the New York Times, and are now the leading cause of death among Americans under 50. This epidemic has led to medical innovations that seek to relieve pain with technology and without the use of highly addictive drugs.
Most of these technologies work by sending electrical signals through the nerves in order to block the pain. Many medical devices using electrical stimulation, such as implantable Spinal Cord Stimulators or non-invasive Transcutaneous Electrical Nerve Stimulators (TENS), block pain by stimulating the nerves. Newer therapies are targeting inflammation instead of nerve-blocking.
Biotech and technology companies are working around the clock to put out a method that works in order to put a halt to the opioid crisis as well as offer effective and efficient pain relief therapies for a diverse set of patients. Additionally, the newly popular blockchain technologies could create an avenue to share and store information across sector the technology and biotech sectors regarding what therapies are working to combat the opioid crisis, and what isn't.
A few companies to look into that are changing both the future of technology and biotechnology alike include: Endonovo Therapeutics, Inc. (OTCQB: ENDV), Neurometrix, Inc. (NASDAQ: NURO), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Bitcoin Investment Trust. (OTCQX: GBTC), and Helios and Matheson Analytics Inc. (NASDAQ: HMNY).
Endonovo Therapeutics, Inc. (OTCQB: ENDV)
Market Cap: $11.6M, current share price: $.038
With the start of commercial sales of its non-invasive medical device, SofPulse', for the palliative treatment of pain and post-surgical edema last month and an announced senior secured redeemable Series C Preferred Stock offering, Endonovo Therapeutics, Inc. (ENDV), a commercial stage developer of non-invasive Electroceuticals, has all the pieces in place for a successful launch of its cutting-edge therapy into the pain relief therapeutics market expected to reach $83 billion by 2024, according to Transparency Market Research. Endonovo's therapy works by treating the underlying cause of the pain itself: inflammation. Additionally, unlike other medical device companies that obtain FDA Clearance, Endonovo has reimbursement from Medicare for the treatment of chronic wounds, which places it advantageously to actually generate revenue from its products. Other companies with similar technologies have= failed to achieve the same clinical results as Endonovo's SofPulse' in clinical trials for reducing pain following breast augmentation surgery. With positive clinical data in the treatment of ischemic cardiomyopathy in patients with failed medical therapy and revascularization options, ENDV is severely undervalued compared to its competitors, which are worth $250 to $320 million in market cap despite having smaller clinical pipelines with less than stellar clinical data and not having commercial stage products.
Neurometrix, Inc. (NASDAQ: NURO)
Market Cap: $9.427M, current share price: $1.32
NURO is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. In early Q1 2018 the Company reported a strategic collaboration with GlaxoSmithKline (GSK) under which GSK Consumer Healthcare acquired Quell market rights outside the US while NeuroMetrix retained ownership for the US market. The companies will co-fund Quell technology development. GSK Consumer Healthcare paid $5 million for the Quell assets related to markets outside the US and will pay up to $21.5 million upon the achievement of certain development and commercialization milestones. Like ENDV's platform, Quell focuses on relieving pain. This technology has the potential to improve reduce the dependency on opioids.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)
Market Cap: $155.79, current share price: $11.49
Zynerba Pharmaceuticals Inc. is a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric diseases with high unmet medical needs. ZYNE is down over 50% from it's highs throughout the last year. This company like ENDV is doing some very exciting things and should be on everyone's watchlist.
Bitcoin Investment Trust. (OTCQB: GBTC)
Market Cap: $2.53B, current share price: $16.44
GBTC is the first publicly bitcoin price based security. The company is being pitched as the best way to invest into bitcoin without having to worry about how to make sure your coins are actually safe. GBTC is up over 1400% from where it was priced just a year ago, keep an eye out for this stock should bitcoin continue to increase in price.
Helios and Matheson Analytics Inc. (NASDAQ: HMNY)
Market Cap: $120.839M, current share price: $5.04
HMNY is a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening, and consumer-centric technology. HMNY owns a majority interest in MoviePass Inc., the nation's premier movie-theater subscription service. HMNY's holdings include RedZone Map', a safety and navigation app for iOS and Android users, and a community-based ecosystem that features a socially empowered safety map app that enhances mobile GPS navigation using advanced proprietary technology.
For Full Legal Disclaimer Click Here.
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS.FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Website: http://microcapspeculators.com/
Content Provided By: Microcap Speculators
Email:info@microcapspecualtors.com
Phone: +1-702-720-6310
Media Contact
FN Media Group LLC
e-mail:editor@financialnewsmedia.com
+1(954)345-0611
